15TH ANNUAL REPORT 2016- 2017





Baroda Address: Village Manglej Nareshwar Road, Taluka Karjan, Dist. Vadodara, Gujarat 391210.





Corporate Information	3
Chairmans letter to Shareholders	4
Managing Directors Message	- 8
Notice Notice	14
Menagement Discussion & Analysis	20
Directors Report	31
e Independent Auditor's Report	73
Annexure to Auditors Report	74
Annexure "A" to Independent Auditor's Report	77
Balance Sheet	81
Statement of Profit & Loss	82
Cash Flow Statement	83
Attendance Slip	11
Proxy Form	11

CORPORATE INFORMATION

BOARD OF DIRECTORS

Mr. Atul Ranchal Mr. Rajesh Mahajan Dr. D.S. Maity

Director Mr. Rajnish Kumar Bedi Mr. Deposk Mahalan

Mr. Deepak Mahajan Ms. Sonia Gupta

CHIEF FINANCIAL OFFICER
Mr. Anil Kumer Pillai

COMPANY SECRETARY
Ms. Jyoti Sancheti

AUDITORS
M/s SGCO & Co.
Chartered Accountants
4A, Kaledonia-HDIL, 2nd Floor,
Sahar Road, Near Andheri Station,
Andheri [East], Mumbai - 400 069
Tel: 022 66256363

BANKERS Kotak Mahindra Bank State Bank of India Indian Bank

Chairman Managing Director CEO cum Technical

Independent Director Independent Director Independent Director REGD. OFFICE & WORKS Unit 1: Village Kishanpura Nalagarh Road Baddi,

Distt. Solan, H.P.- 174101 Tel.: 01795- 654001/02/03

Fax: 01795-236939

Unit 2: Baroda Address: Village Manglej Nareshwar Road, Taluka Karjan, Dist Vadodara, Gujarat: 391210.

CORPORATE OFFICE

502, Kanakia Atrium -2, Next to Hotel Courtyard Marriott Andheri Kurta Road, Andheri (East), Mumbai - 400093

Tel.: 022-61933100 / Fax.: 022-61933114 email:investors@brookslabs.net website:www.brookslabs.net

CIN: L24232HP2002PLC 00026

REGISTRAR & SHARE TRANSFER AGENT Link Intime India Pvt. Ltd., C-101,247 Park, L.B.S.Marg, Vikhroli (W),

Mumbai- 400083 Tel: 022-49186000



CHAIRMANS LETTER

Dear Shareholders,

Last few years have been particularly challenging for our industry in India as well as globally. The pharmaceutical industry is witnessing a slow rate of growth due to factors like increasing regulatory & compliance issues and pricing pressures across markets. There were several changes in the pharmaceutical eco-system.

However, despite all these challenges and changes, we stand strong. During the year, we identified several improvement areas in our current processes and capacities which will give us encouraging outcomes in the near future.

We also laid emphasis on building our base by automating our processes as our markets got tougher in regulations. We are not only adhering to new tougher regulations but also expanding our capacities too as we have better demand. So we are directed in our efforts towards strengthening our core capabilities through a stronger focus on better technology with enhanced capacities.

In the future too, we shall continue to increase our current capacities, make our presence felt in the international markets, though international highly regulated markets take their own sweet time for approvals and registrations, we at Brooks are leaving no stone unturned to keep it going at best

possible pace with our serious efforts and continuous improvement through focus on global compliances with better quality and processes.

We remain optimistic and continue to act with resilience. With commencement of operations at Vadodara, 2017-18 is an important year for the organisation and we are excited to have you on board in this journey with us. As we move towards the new growth trajectory, we remain committed to build a strong organisation. We strive to create a culture that attracts and retains the best talent as we look to expand our global footprints.

At Brooks, we have always been committed for patients across the world and towards creating value to our stakeholders. Although the year under review has been challenging, your organisation remains well poised for continuous and sustained growth. Our aim is to transform the organisation to an innovative company and deliver our best.

Keeping the above in mind, we strive to maintain our excellence in quality, safety, and compliance at Baddi and Vadodara facilities. We will continue to deliver on your expectations with increased profitability and improved cash flows in the coming years. Your continuous support towards the Company's endeavours and the commitment of our outstanding employees gives me immense faith and confidence in the future of our Company.

Place: Mumbai
Date: 02.09.2017

Atul Ranchal Chairman, Brooks Laboratories Ltd.



MANAGING DIRECTOR'S SPEECH

Dear Shareholders,

It gives me great pleasure to share with you some insights about your Company and the pharma industry at large.

Our performance during the year was moderate and the reasons for the same can be attributed to the end of excise exemption at our Baddi facility which made it difficult to compete at price levels. We have invested in expansion and upgradation activities during the year. Global pharma industry at large is facing a slow growth which has impacted our business too.

We are working hard each day to grow our Company and achieve the targeted milestones.

New facility in Vadodora, Gujarat

We inaugurated our new manufacturing facility at Vadodara in March this year. Our Vadodara plant is a state-of-the-art and a fully compliant facility, which would help us serve our growing business by catering to domestic and global markets. We are confident of placing ourselves into the next higher orbit of growth and generate sustainable and profitable revenues.

I would like to share with you our focus areas for this year:

- Optimum capacity utilization
- World class systems


- Catering to global customer base
- Create an impact


We have elaborated the focus areas in following pages.

I would like to take this opportunity to thank all our valued colleagues, investors, and other stakeholders at Brooks Laboratories. I am optimistic about our Company's future and the growth that we can achieve.



Place: Mumbai Date: 02.09.2017 Rajesh Mahajan Managing Director, Brooks Laboratories Ltd.





Our strategy going forward is to optimize our operating capacity in our Badal and Vadodara facilities. Keeping this in mind, we have upgraded our injectable. nanufacturing line. With both our world class facilities operating at our Baddi plant in line with compand improved our injectable naxinum capacity, our performance in the coming years will improve and we will see better revenues and profitability.

